Larazotide acetate compositions
AssigneeAlba Therapeutics Corporation
InventorsRoland Callens, Georges Blondeel, Thierry Delplanche
Life of this patent
Estimating the term…
Abstract
The invention provides crystalline forms of the peptide Gly-Gly-Val-Leu-Val-Gln-Pro-Gly (SEQ ID NO 1), and salts of the peptide, which may further have associated water molecules. These salts and hydrated salts of the peptide and compositions comprising these materials have advantageous pharmaceutical properties.
Claims19
A crystalline salt of the peptide Gly-Gly-Val-Leu-Val-Gln-Pro-Gly (SEQ ID NO 1), wherein the salt of the peptide is selected from hydrochloride or acetate.
A crystalline acetate salt of the peptide Gly-Gly-Val-Leu-Val-Gln-Pro-Gly (SEQ ID NO 1) having an XRPD pattern comprising one or more peaks selected from 9.08±0.2 degrees 2θ, 9.52±0.2 degrees 2θ, 10.34±0.2 degrees 2θ, and/or 14.24±0.2 degrees 2θ.
An acetate salt of the peptide Gly-Gly-Val-Leu-Val-Gln-Pro-Gly (SEQ ID NO 1) having an acetate concentration of less than about 10 mole % and optionally a water concentration of less than about 7 mole %.
An isolated chloride salt of the peptide Gly-Gly-Val-Leu-Val-Gln-Pro-Gly (SEQ ID NO 1) with a purity of at least 98.5% as determined by HPLC.
Dependencies are inferred from the claim text.